AI-Guided CBT for Depression and Anxiety (AI-CBT-DA)
The Significance of Artificial Intelligence-Guided Psychotherapy of Depression and Anxiety Disorders
This study aims to evaluate the effectiveness of an artificial intelligence (AI)-guided cognitive behavioral therapy (CBT) program for the treatment of mild depression and anxiety disorders in adults.
Depression and anxiety disorders are among the most common mental health conditions worldwide and are associated with significant individual and societal burden. Despite the availability of effective treatments, access to psychotherapy remains limited due to insufficient resources and long waiting times. Digital mental health interventions, particularly those supported by artificial intelligence, have the potential to increase accessibility and scalability of evidence-based treatments.
In this controlled clinical trial, participants diagnosed with mild depressive disorder and/or anxiety disorders will be assigned to either an experimental group receiving AI-guided CBT or a control group receiving standard psychiatric care. The intervention will be delivered through a digital platform and will consist of structured weekly sessions over a 10-week period.
The primary objective of the study is to assess changes in symptoms of depression and anxiety. Secondary outcomes include perceived stress, social support, digital therapeutic alliance, and overall clinical improvement.
The findings of this study are expected to contribute to the understanding of the role of AI in psychotherapy and its potential to improve access to mental health care.
調査の概要
状態
詳細な説明
This study is designed as a controlled clinical trial to investigate the effectiveness of an artificial intelligence (AI)-guided cognitive behavioral therapy (CBT) intervention in adults with mild depressive disorder and/or anxiety disorders.
Mental health disorders, particularly depression and anxiety, represent a major public health challenge. Although cognitive behavioral therapy is an evidence-based treatment, access to psychotherapy remains limited in many healthcare systems. AI-guided digital interventions may provide a scalable and accessible alternative or complement to traditional therapy.
Participants aged 18 years and older with a diagnosis of mild depression and/or anxiety disorders, confirmed using a structured diagnostic interview, will be recruited from outpatient services at the University Clinical Center Niš. Eligible participants will be allocated to one of two groups: (1) an experimental group receiving AI-guided CBT through a digital platform, and (2) a control group receiving standard psychiatric care.
The intervention will consist of weekly structured sessions lasting approximately 45-60 minutes over a period of 10 weeks. Sessions will be conducted using a digital platform designed to deliver CBT-based content with guidance from an AI system. The intervention will be conducted in a clinical setting with supervision by trained clinicians.
Assessments will be conducted at baseline, mid-treatment (after 5 weeks), and post-treatment (after 10 weeks). Outcome measures will include standardized scales for depression, anxiety, perceived stress, social support, and digital therapeutic alliance. Clinical global impression scales will also be used to evaluate overall improvement.
The study will also explore mechanisms of change, including the role of digital therapeutic alliance and cognitive-behavioral processes in symptom reduction.
All participants will provide informed consent prior to participation. Data will be anonymized and handled in accordance with ethical and data protection standards.
The results of this study are expected to provide evidence on the clinical utility of AI-guided psychotherapy and inform future integration of digital mental health interventions into routine clinical practice.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前：Aleksandra Stojanović, MD, PHD candidate
- 電話番号：+381642293541
- メール：drakiwatson@gmail.com
研究場所
-
-
-
Niš、セルビア、18000
- 募集
- University Clinical Center Nis
-
コンタクト：
- Aleksandra Stojanović, MD, PHD candidate
- 電話番号：+381642293541
- メール：drakiwatson@gmail.com
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
Age 18 years or older Diagnosis of mild depressive disorder and/or anxiety disorder confirmed by a structured clinical interview (MINI) Ability to understand and provide informed consent Access to a device capable of using the digital platform (computer, tablet, or smartphone) Willingness to participate in weekly sessions over a 10-week period
Exclusion Criteria:
Moderate to severe depressive disorder Current or past diagnosis of psychotic disorder Bipolar disorder Substance use disorder or dependence Primary diagnosis of antisocial personality disorder Severe cognitive impairment or inability to use digital tools Acute suicidal risk requiring immediate intervention Concurrent participation in another structured psychotherapy program-
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：非ランダム化
- 介入モデル：並列代入
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：AI-Guided CBT
Participants in this group will receive AI-guided cognitive behavioral therapy delivered through a digital platform.
The intervention will consist of structured weekly sessions lasting 45-60 minutes over a period of 10 weeks, conducted under clinical supervision.
|
AI-guided cognitive behavioral therapy delivered through a digital platform, consisting of structured weekly sessions over 10 weeks.
|
|
アクティブコンパレータ：Traditional CBT
Participants in this group will receive standard psychiatric care, including routine clinical monitoring and treatment as determined by their treating clinician, without access to the AI-guided CBT intervention.
|
Cognitive behavioral therapy delivered by a trained therapist in a standard clinical format, consisting of structured weekly sessions over a 10-week period.
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in depressive symptom severity
時間枠：Baseline, week 5, and week 10
|
Change in depressive symptoms measured by the Patient Health Questionnaire-9 (PHQ-9).
Higher scores indicate greater depressive symptom severity.
|
Baseline, week 5, and week 10
|
|
Change in anxiety symptom severity
時間枠：Baseline, week 5, and week 10
|
Change in anxiety symptoms measured by the Generalized Anxiety Disorder-7 scale (GAD-7).
Higher scores indicate greater anxiety symptom severity.
|
Baseline, week 5, and week 10
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in perceived stress
時間枠：Baseline, week 5, and week 10
|
Change in perceived stress measured by the Perceived Stress Scale (PSS).
|
Baseline, week 5, and week 10
|
|
Change in perceived social support
時間枠：Baseline and week 10
|
Change in perceived social support measured by the Multidimensional Scale of Perceived Social Support (MSPSS).
|
Baseline and week 10
|
|
Digital therapeutic alliance
時間枠：Week 10
|
Therapeutic alliance measured using the Digital Working Alliance Inventory (D-WAI).
|
Week 10
|
|
Clinical global improvement
時間枠：Week 5, week 10
|
Overall clinical improvement measured using the Clinical Global Impression - Improvement scale (CGI-I).
|
Week 5, week 10
|
|
Clinical severity of illness
時間枠：Baseline, week 5, week 10
|
Severity of illness measured using the Clinical Global Impression - Severity scale (CGI-S).
|
Baseline, week 5, week 10
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
- AI-CBT-UKCNIS-2026 (その他の識別子：University Clinical Center Niš, Center for Mental Health)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。